Automated and Closed Cell Therapy Market
According to Intent Market Research, the Automated and Closed Cell Therapy Market is expected to grow from USD 5.7 billion in 2023 at a CAGR of 13.2% to touch USD 13.7 billion by 2030. The Automated and Closed Cell Therapy Market is dominated by key players such as Novartis AG, Gilead Sciences, Bayer AG, Stryker Corporation, Kite Pharma (A Gilead Company), Lonza Group, Celyad, Mesoblast Limited, Celgene Corporation (Acquired by Bristol-Myers Squibb), Bluebird Bio, Stemline Therapeutics, Kiadis Pharma, Orchard Therapeutics, TCR2 Therapeutics, Fujifilm Cellular Dynamics.